Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications
NCT01518101 on ClinicalTrials.gov · last registry update 2017-02-27
Finished October 2012, after enrolling 62 people. Primary outcome, as filed: Proportion of patients preferring each treatment regimen. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Enrollment
- 62
- Started
- 2012-01
- Primary completion
- 2012-10 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Proportion of patients preferring each treatment regimen
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.